Opportunity Information: Apply for RFA AG 24 023
The National Institutes of Health (NIH) funding opportunity RFA-AG-24-023 supports preclinical research aimed at clarifying how exposure to environmental toxicants influences brain aging and increases risk for Alzheimer’s disease (AD) and AD-related dementias (ADRD). The program is focused on late-onset Alzheimer’s disease (LOAD) and is specifically designed to fund studies in mouse models, not human clinical trials. The intent is to move beyond simple associations by measuring, in a controlled experimental setting, what these toxicant exposures actually do to the brain at the molecular, pathological, and functional levels across the lifespan.
A key emphasis of the initiative is timing of exposure. Proposed projects are expected to test exposures occurring in early life and mid-life and then evaluate consequences that emerge later in life, mirroring the long latency seen in human neurodegenerative disease. To accomplish this, the announcement calls for cross-sectional and/or longitudinal study designs paired with multi-modal phenotyping. In practical terms, that means collecting a broad, integrated set of outcomes such as molecular and biochemical measures, neuropathology, and behavioral or functional readouts in mouse LOAD models, with the goal of building a more complete picture of how toxicants shape disease-relevant trajectories over time.
Another central requirement is that studies account for biological variables that are known to alter AD risk and presentation. The opportunity highlights the importance of genetic diversity and sex differences in exposure-related outcomes, signaling that strong applications should be designed to test whether toxicant effects vary by sex and by genetic background rather than assuming a one-size-fits-all effect. This aligns with the broader AD field’s recognition that both genetics and sex can substantially modify vulnerability, pathology burden, and cognitive/behavioral manifestations.
The mechanism is a U01 cooperative agreement, which typically indicates a more collaborative, NIH-involved funding structure than a standard research project grant. While applicants still lead the science, cooperative agreements generally involve substantial scientific interaction with NIH program staff and may include shared expectations around milestones, coordination, and data/resource sharing consistent with program goals. The opportunity is labeled “Clinical Trial Not Allowed,” reinforcing that the work must remain preclinical and mechanistic rather than interventional studies in humans.
In terms of who can apply, eligibility is broad and includes many types of domestic and non-domestic institutions and organizations. Eligible applicants include state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits (with or without 501(c)(3) status); for-profit organizations (including small businesses); and other entities. The announcement also explicitly calls out additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, tribal governments that are not federally recognized, and foreign organizations.
Administrative details from the source data indicate the opportunity falls under the Health category (CFDA 93.866), is offered by NIH, and uses the cooperative agreement funding instrument. The original closing date listed is October 23, 2023, with an award ceiling of $1,250,000. The expected number of awards is not specified in the provided data. Overall, the funding opportunity is designed to generate rigorous, mechanistic preclinical evidence on how major AD/ADRD-associated toxicants influence aging brains, and to do so in ways that reflect real-world complexity by incorporating lifespan timing, multi-system outcome measures, genetic diversity, and sex as core elements of study design.Apply for RFA AG 24 023
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Preclinical Studies to Characterize the Impact of Toxicants on Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2023-05-15.
- Applicants must submit their applications by 2023-10-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,250,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Health
Next opportunity: Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Previous opportunity: Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 24 023
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 24 023) also looked into and applied for these:
| Funding Opportunity |
|---|
| Quantifying the Impact of Environmental Toxicants on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Risk in Cohort Studies (U01 Clinical Trial Not Allowed) Apply for RFA AG 24 022 Funding Number: RFA AG 24 022 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Significance of Clonal Hematopoiesis (CH) in Aging Humans (R01 Clinical Trial Not Allowed)? Apply for RFA AG 24 038 Funding Number: RFA AG 24 038 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Measuring Financial Hardship Among People and Families Living with AD/ADRD (R01 Clinical Trial Not Allowed)? Apply for RFA AG 24 036 Funding Number: RFA AG 24 036 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Health Information Systems (HIS) Activity Apply for 72052123RFI00001 Funding Number: 72052123RFI00001 Agency: Haiti USAID-Port Au Prince Category: Health Funding Amount: Case Dependent |
| Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed) Apply for RFA NS 24 003 Funding Number: RFA NS 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $1,300,000 |
| Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) Apply for PAR 23 211 Funding Number: PAR 23 211 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed) Apply for PAR 23 212 Funding Number: PAR 23 212 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIMHD Centers of Excellence in Investigator Development and Community Engagement (P50 - Clinical Trial Optional) Apply for RFA MD 23 011 Funding Number: RFA MD 23 011 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Accelerating Behavioral and Social Science through Ontology Development and Use: Dissemination and Coordination Center (U24) Clinical Trial Not Allowed Apply for PAR 23 181 Funding Number: PAR 23 181 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Specialized Alcohol Research Centers (P50 Clinical trial Optional) Apply for RFA AA 23 001 Funding Number: RFA AA 23 001 Agency: National Institutes of Health Category: Health Funding Amount: $1,150,000 |
| Comprehensive Alcohol Research Centers (P60 Clinical trial Optional) Apply for RFA AA 23 002 Funding Number: RFA AA 23 002 Agency: National Institutes of Health Category: Health Funding Amount: $1,250,000 |
| NEI Collaborative Clinical Vision Research: Chair's Grant (UG1-Clinical Trial Required) Apply for PAR 23 209 Funding Number: PAR 23 209 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Collaborative Clinical Vision Research Project: Resource Center Grant (UG1 Clinical Trial Required) Apply for PAR 23 201 Funding Number: PAR 23 201 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed) Apply for PAR 23 126 Funding Number: PAR 23 126 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required) Apply for PAR 23 204 Funding Number: PAR 23 204 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Enhancing Use of Harmonized Cognitive Assessment Protocol Data?(R01 Clinical Trial Not Allowed) Apply for RFA AG 24 032 Funding Number: RFA AG 24 032 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) Apply for PAR 23 206 Funding Number: PAR 23 206 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) Apply for PAR 23 198 Funding Number: PAR 23 198 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional) Apply for RFA MH 24 120 Funding Number: RFA MH 24 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional) Apply for RFA HG 23 018 Funding Number: RFA HG 23 018 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 24 023", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.